Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Isocitrate Dehydrogenase (IDH) Inhibitors Market Snapshot

The global isocitrate dehydrogenase (IDH) inhibitors market garnered a market value of US$ 1.7 Billion in 2022 and is expected to accumulate a market value of US$ 39.16 Billion by registering a CAGR of 33% in the forecast period 2023 to 2033.

The market's growth can be attributed to the rising occurrence of IDH-mutated cancers, such as acute myeloid leukemia (AML) and cholangiocarcinoma, which are frequently managed using IDH inhibitors. The market for isocitrate dehydrogenase (IDH) inhibitors registered a CAGR of 18% in the historical period 2018 to 2022

Isocitrate dehydrogenase (IDH) inhibitors are a class of drugs that target the mutated form of the IDH enzyme found in certain types of cancer cells. These drugs work by blocking the activity of the mutated IDH enzyme, which is involved in the development and progression of cancer.

The IDH inhibitors market refers to the pharmaceutical industry's production and sale of these drugs. This market has grown significantly in recent years, with the approval of several IDH inhibitors by regulatory agencies such as the FDA and the EMA.

IDH inhibitors are primarily used in the treatment of acute myeloid leukemia (AML) and other types of cancers, such as cholangiocarcinoma and glioma, that have mutations in the IDH gene. The market for IDH inhibitors is expected to continue to grow as more research is conducted on the use of these drugs in the treatment of cancer.

Report Attribute Details
Expected Market Value (2023) US$ 2.26 Billion
Anticipated Forecast Value (2033) US$ 39.16 Billion
Projected Growth Rate (2023 to 2033) 33% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Isocitrate Dehydrogenase (IDH) Inhibitors Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights- the market for Isocitrate dehydrogenase (IDH) inhibitors reflected a value of 18% during the historical period, 2018 to 2022.

The market is expected to be driven by several factors, including the growing incidence of cancer, the increasing adoption of personalized medicine, and the development of targeted therapies for cancer treatment. The availability of favorable regulatory frameworks for the approval of IDH inhibitors is also expected to drive growth in the market.

In terms of geography, North America has been the largest market for IDH inhibitors, followed by Europe and Asia-Pacific. However, the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period, driven by the growing prevalence of cancer in the region and increasing investment in healthcare infrastructure.

Overall, the IDH inhibitors market is expected to continue to grow over the forecast period, driven by increasing demand for more effective and targeted cancer treatments.

Thus, the market for Isocitrate dehydrogenase (IDH) inhibitors is expected to register a CAGR of 33% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of Isocitrate Dehydrogenase (IDH) Inhibitors Market?

Increasing incidence of cancer driving the growth of IDH inhibitors market

The incidence of cancer is on the rise globally, and IDH inhibitors are a promising new class of drugs that offer targeted therapy for specific types of cancers. IDH mutations are found in a high percentage of certain types of cancers, such as AML, cholangiocarcinoma, and glioma. This provides a significant opportunity for the development and use of IDH inhibitors as a treatment option.

Advances in drug discovery and development techniques have enabled the identification and development of targeted therapies, such as IDH inhibitors, with greater efficacy and fewer side effects.

The regulatory environment for IDH inhibitors has been favorable, with several drugs already approved by regulatory agencies such as the FDA and EMA. This has encouraged investment in research and development of these drugs.

IDH inhibitors represent a targeted therapy that can be tailored to the specific genetic makeup of an individual's cancer. As demand for personalized medicine grows, the market for IDH inhibitors is likely to expand.

Development in inhibitors shaping the landscape for IDH inhibitors market

IDH1 inhibitors: These inhibitors specifically target the mutated form of the IDH1 enzyme, which is found in certain types of cancers such as cholangiocarcinoma and glioma. Examples of IDH1 inhibitors include ivosidenib (Tibsovo) and enasidenib (Idhifa), which have been approved by the FDA for the treatment of AML with IDH1 mutations.

IDH2 inhibitors: These inhibitors specifically target the mutated form of the IDH2 enzyme, which is found in certain types of cancers such as AML. Examples of IDH2 inhibitors include agios (AG-221), ivosidenib (Tibsovo), and enasidenib (Idhifa), which have been approved by the FDA for the treatment of AML with IDH2 mutations.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the Isocitrate Dehydrogenase (IDH) Inhibitors Market?

Limited patient population along with high drug development costs derailing market growth

IDH inhibitors are only effective in patients with specific genetic mutations in the IDH gene, which limits the eligible patient population for these drugs. This means that the market potential for IDH inhibitors is relatively small compared to other cancer therapies.

Developing targeted therapies such as IDH inhibitors can be expensive, and the costs associated with research and development may be passed on to consumers in the form of high drug prices. The market for cancer therapies is highly competitive, and there are several established treatments available for many types of cancers. IDH inhibitors face competition from other targeted therapies as well as traditional chemotherapy and radiation treatments.

Patients may develop resistance to IDH inhibitors over time, which can limit the effectiveness of these drugs in the long term. Like all drugs, IDH inhibitors can cause adverse effects, and patients may experience side effects such as nausea, vomiting, and fatigue. Managing these side effects can be challenging for both patients and healthcare providers. All these factors are hampering the market growth of IDH inhibitors market.

Region-Wise Insights

Increasing Use of Targeted Therapies Favoring Market Growth for IDH Inhibitors in North America?

Presence of key market players bolstering the market growth for IDH inhibitors market in North America

The North America Isocitrate Dehydrogenase (IDH) inhibitors market is one of the largest markets for these drugs globally. The market is primarily driven by the high prevalence of cancer in the region and the increasing use of targeted therapies for cancer treatment.

In North America, the United States is the largest market for IDH inhibitors, followed by Canada. The FDA has approved several IDH inhibitors for the treatment of AML and other types of cancers, which has contributed to the growth of the market.

Moreover, the presence of key players in the region, such as Agios Pharmaceuticals, Celgene Corporation, and Daiichi Sankyo, has also fueled the growth of the market. These companies have invested heavily in research and development to bring new IDH inhibitors to the market. Thus, North America is expected to possess 46% market share for IDH inhibitors market in 2023.

Increasing Research and Development Activities Crating Lucrative Opportunities for IDH Inhibitors Market in Europe

Growing incidence of cancer in Europe boosting market growth of ISH inhibitors

The incidence of cancer is on the rise in Europe, and this is driving demand for more effective cancer treatments such as IDH inhibitors. Pharmaceutical companies are investing heavily in research and development of IDH inhibitors to develop more effective and targeted therapies for cancer treatment.

The European Medicines Agency (EMA) has granted accelerated approval to several IDH inhibitors, which has created a favorable regulatory environment for the development and commercialization of these drugs.

IDH inhibitors are a type of personalized medicine that targets specific mutations in cancer cells, and as awareness about personalized medicine grows, demand for IDH inhibitors is also increasing.

There is a strong pipeline of IDH inhibitors in Europe, with several drugs in various stages of clinical trials. This is expected to drive growth in the market in the coming years. Thus, Europe is expected to possess 43% market share for IDH inhibitors market in 2023.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

Convenience of Consuming IDH inhibitors Orally Making them Favorable to Use?

Fewer side effects of oral IDH inhibitors making them easier for consumption

By route of administration, the IDH inhibitors market is segmented into Oral, Parenteral and Subcutaneous

Oral Isocitrate Dehydrogenase (IDH) inhibitors are one of the types of IDH inhibitors used in cancer therapy. Oral IDH inhibitors have certain advantages over other types of cancer therapies, such as chemotherapy, which is typically administered intravenously. Oral medications can be taken at home, and they may have fewer side effects than chemotherapy. Additionally, oral IDH inhibitors are often more targeted and may be more effective against cancer cells with specific IDH mutations.

Thus, by route of administration, oral IDH inhibitors is expected to possess 49% market share for IDH inhibitors market in 2023.

Market Competition

Key players in the isocitrate dehydrogenase (IDH) inhibitors market are Bayer, Agios Pharma, Daiichi Sankyo, Ohm Oncology, Celgene, Philogen S.p.A., Tragara, Aslan Pharmaceuticals, Pfizer, Inc. and Sun Pharmaceutical Industries Ltd.

  • Bayer's lead IDH inhibitor candidate is called BAY 1436032, which is an oral small molecule inhibitor of the mutated IDH1 enzyme. The drug has been shown to inhibit the production of the oncometabolite 2-hydroxyglutarate (2-HG) and induce differentiation of leukemia cells in preclinical studies.
  • Agios has developed enasidenib (AG-221), an oral small molecule inhibitor of the mutated IDH2 enzyme. Enasidenib works by inhibiting the production of the oncometabolite 2-HG and inducing differentiation of leukemia cells. Enasidenib has been approved by the US FDA for the treatment of relapsed or refractory AML with an IDH2 mutation.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 2.26 Billion
Market Value in 2033 US$ 39.16 Billion
Growth Rate CAGR of 33% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
  • Type
  • Molecule Type
  • Route of Administration
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Mexico
  • Rest of Latin America
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • Rest of Europe
  • India
  • Malaysia
  • Singapore
  • Thailand
  • Rest of South Asia
  • China
  • Japan
  • South Korea
  • Austria
  • New Zealand
  • GCC countries
  • South Africa
  • Israel
  • Rest of MEA
Key Companies Profiled
  • Bayer
  • Agios Pharma
  • Daiichi Sankyo
  • Ohm Oncology
  • Celgene
  • Philogen S.p.A.
  • Tragara
  • Aslan Pharmaceuticals
  • Pfizer, Inc.
  • Sun Pharmaceutical Industries Ltd.
Customization Available Upon Request

Key Segments Profiled in the Isocitrate Dehydrogenase (IDH) Inhibitors Industry Survey

Type:

  • IDH1 Mutant Medullary Malignant Tumor
  • IDH2 Mutant Medullary Malignant Tumor
  • Peptides
  • Small Molecule
  • Others

Molecule Types:

  • Monoclonal Antibody
  • Peptides
  • Small Molecules
  • Others

Route of Administration:

  • Oral
  • Parenteral
  • Subcutaneous

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

What is the Isocitrate Dehydrogenase (IDH) Inhibitors Market Worth?

The global market is worth US$ 2.26 billion in 2023.

What is the Projected Growth Rate for the Market?

The market is anticipated to thrive at a 33% CAGR from 2023 to 2033.

What was the Previous CAGR of the market?

The market expanded at an 18% CAGR from 2018 to 2022.

What is Europe’s Share in the Isocitrate Dehydrogenase (IDH) Inhibitors Market?

Europe’s holds nearly 43% of the market share in 2023.

What is the Leading Route of Administration in the Market?

The oral IDH inhibitors segment leads, with 49% of the market share in 2023.

Table of Content

1. Executive Summary | Isocitrate Dehydrogenase (IDH) Inhibitors Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033

        5.3.1. IDH1 Mutant Medullary Malignant Tumor

        5.3.2. IDH2 Mutant Medullary Malignant Tumor

    5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, ByMolecule Types

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis ByMolecule Types, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast ByMolecule Types, 2023 to 2033

        6.3.1. Monoclonal Antibody

        6.3.2. Peptides

        6.3.3. Small molecule

        6.3.4. Others

    6.4. Y-o-Y Growth Trend Analysis ByMolecule Types, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis ByMolecule Types, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033

        7.3.1. Oral

        7.3.2. Parenteral

        7.3.3. Subcutaneous

        7.3.4. Topical

    7.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. South Asia

        8.3.5. East Asia

        8.3.6. Oceania

        8.3.7. MEA

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Type

        9.2.3. ByMolecule Types

        9.2.4. By Route of Administration

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Type

        9.3.3. ByMolecule Types

        9.3.4. By Route of Administration

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Type

        10.2.3. ByMolecule Types

        10.2.4. By Route of Administration

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Type

        10.3.3. ByMolecule Types

        10.3.4. By Route of Administration

    10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United Kingdom

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Type

        11.2.3. ByMolecule Types

        11.2.4. By Route of Administration

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Type

        11.3.3. ByMolecule Types

        11.3.4. By Route of Administration

    11.4. Key Takeaways

12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Malaysia

            12.2.1.3. Singapore

            12.2.1.4. Thailand

            12.2.1.5. Rest of South Asia

        12.2.2. By Type

        12.2.3. ByMolecule Types

        12.2.4. By Route of Administration

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Type

        12.3.3. ByMolecule Types

        12.3.4. By Route of Administration

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Type

        13.2.3. ByMolecule Types

        13.2.4. By Route of Administration

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Type

        13.3.3. ByMolecule Types

        13.3.4. By Route of Administration

    13.4. Key Takeaways

14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. Australia

            14.2.1.2. New Zealand

        14.2.2. By Type

        14.2.3. ByMolecule Types

        14.2.4. By Route of Administration

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Type

        14.3.3. ByMolecule Types

        14.3.4. By Route of Administration

    14.4. Key Takeaways

15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Type

        15.2.3. ByMolecule Types

        15.2.4. By Route of Administration

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Type

        15.3.3. ByMolecule Types

        15.3.4. By Route of Administration

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Type

            16.1.2.2. ByMolecule Types

            16.1.2.3. By Route of Administration

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Type

            16.2.2.2. ByMolecule Types

            16.2.2.3. By Route of Administration

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Type

            16.3.2.2. ByMolecule Types

            16.3.2.3. By Route of Administration

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Type

            16.4.2.2. ByMolecule Types

            16.4.2.3. By Route of Administration

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Type

            16.5.2.2. ByMolecule Types

            16.5.2.3. By Route of Administration

    16.6. United Kingdom

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Type

            16.6.2.2. ByMolecule Types

            16.6.2.3. By Route of Administration

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Type

            16.7.2.2. ByMolecule Types

            16.7.2.3. By Route of Administration

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Type

            16.8.2.2. ByMolecule Types

            16.8.2.3. By Route of Administration

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Type

            16.9.2.2. ByMolecule Types

            16.9.2.3. By Route of Administration

    16.10. India

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Type

            16.10.2.2. ByMolecule Types

            16.10.2.3. By Route of Administration

    16.11. Malaysia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Type

            16.11.2.2. ByMolecule Types

            16.11.2.3. By Route of Administration

    16.12. Singapore

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Type

            16.12.2.2. ByMolecule Types

            16.12.2.3. By Route of Administration

    16.13. Thailand

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Type

            16.13.2.2. ByMolecule Types

            16.13.2.3. By Route of Administration

    16.14. China

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Type

            16.14.2.2. ByMolecule Types

            16.14.2.3. By Route of Administration

    16.15. Japan

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Type

            16.15.2.2. ByMolecule Types

            16.15.2.3. By Route of Administration

    16.16. South Korea

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Type

            16.16.2.2. ByMolecule Types

            16.16.2.3. By Route of Administration

    16.17. Australia

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Type

            16.17.2.2. ByMolecule Types

            16.17.2.3. By Route of Administration

    16.18. New Zealand

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Type

            16.18.2.2. ByMolecule Types

            16.18.2.3. By Route of Administration

    16.19. GCC Countries

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Type

            16.19.2.2. ByMolecule Types

            16.19.2.3. By Route of Administration

    16.20. South Africa

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Type

            16.20.2.2. ByMolecule Types

            16.20.2.3. By Route of Administration

    16.21. Israel

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Type

            16.21.2.2. ByMolecule Types

            16.21.2.3. By Route of Administration

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Type

        17.3.3. By Molecule Types

        17.3.4. By Route of Administration

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Bayer

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. Agios Pharma

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Daiichi Sankyo

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Ohm Oncology

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Celgene

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. Philogen S.p.A.

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Tragara

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Aslan Pharmaceuticals

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Pfizer, Inc.

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. Sun Pharmaceutical Industries Ltd.

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Type, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Molecule Types, 2018 to 2033

Table 4: Global Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Type, 2018 to 2033

Table 7: North America Market Value (US$ Million) Forecast by Molecule Types, 2018 to 2033

Table 8: North America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 10: Latin America Market Value (US$ Million) Forecast by Type, 2018 to 2033

Table 11: Latin America Market Value (US$ Million) Forecast by Molecule Types, 2018 to 2033

Table 12: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Europe Market Value (US$ Million) Forecast by Type, 2018 to 2033

Table 15: Europe Market Value (US$ Million) Forecast by  Molecule Types, 2018 to 2033

Table 16: Europe Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 18: South Asia Market Value (US$ Million) Forecast by Type, 2018 to 2033

Table 19: South Asia Market Value (US$ Million) Forecast by  Molecule Types, 2018 to 2033

Table 20: South Asia Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 22: East Asia Market Value (US$ Million) Forecast by Type, 2018 to 2033

Table 23: East Asia Market Value (US$ Million) Forecast by  Molecule Types, 2018 to 2033

Table 24: East Asia Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 26: Oceania Market Value (US$ Million) Forecast by Type, 2018 to 2033

Table 27: Oceania Market Value (US$ Million) Forecast by  Molecule Types, 2018 to 2033

Table 28: Oceania Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 29: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 30: MEA Market Value (US$ Million) Forecast by Type, 2018 to 2033

Table 31: MEA Market Value (US$ Million) Forecast by  Molecule Types, 2018 to 2033

Table 32: MEA Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ Million) by Type, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by  Molecule Types, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 8: Global Market Value (US$ Million) Analysis by Type, 2018 to 2033

Figure 9: Global Market Value Share (%) and BPS Analysis by Type, 2023 to 2033

Figure 10: Global Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033

Figure 11: Global Market Value (US$ Million) Analysis by  Molecule Types, 2018 to 2033

Figure 12: Global Market Value Share (%) and BPS Analysis by  Molecule Types, 2023 to 2033

Figure 13: Global Market Y-o-Y Growth (%) Projections by  Molecule Types, 2023 to 2033

Figure 14: Global Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 15: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 16: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 17: Global Market Attractiveness by Type, 2023 to 2033

Figure 18: Global Market Attractiveness by  Molecule Types, 2023 to 2033

Figure 19: Global Market Attractiveness by Route of Administration, 2023 to 2033

Figure 20: Global Market Attractiveness by Region, 2023 to 2033

Figure 21: North America Market Value (US$ Million) by Type, 2023 to 2033

Figure 22: North America Market Value (US$ Million) by  Molecule Types, 2023 to 2033

Figure 23: North America Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 28: North America Market Value (US$ Million) Analysis by Type, 2018 to 2033

Figure 29: North America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033

Figure 30: North America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033

Figure 31: North America Market Value (US$ Million) Analysis by  Molecule Types, 2018 to 2033

Figure 32: North America Market Value Share (%) and BPS Analysis by  Molecule Types, 2023 to 2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by  Molecule Types, 2023 to 2033

Figure 34: North America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 35: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 37: North America Market Attractiveness by Type, 2023 to 2033

Figure 38: North America Market Attractiveness by  Molecule Types, 2023 to 2033

Figure 39: North America Market Attractiveness by Route of Administration, 2023 to 2033

Figure 40: North America Market Attractiveness by Country, 2023 to 2033

Figure 41: Latin America Market Value (US$ Million) by Type, 2023 to 2033

Figure 42: Latin America Market Value (US$ Million) by  Molecule Types, 2023 to 2033

Figure 43: Latin America Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 48: Latin America Market Value (US$ Million) Analysis by Type, 2018 to 2033

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033

Figure 51: Latin America Market Value (US$ Million) Analysis by  Molecule Types, 2018 to 2033

Figure 52: Latin America Market Value Share (%) and BPS Analysis by  Molecule Types, 2023 to 2033

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by  Molecule Types, 2023 to 2033

Figure 54: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 55: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 57: Latin America Market Attractiveness by Type, 2023 to 2033

Figure 58: Latin America Market Attractiveness by  Molecule Types, 2023 to 2033

Figure 59: Latin America Market Attractiveness by Route of Administration, 2023 to 2033

Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 61: Europe Market Value (US$ Million) by Type, 2023 to 2033

Figure 62: Europe Market Value (US$ Million) by  Molecule Types, 2023 to 2033

Figure 63: Europe Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 68: Europe Market Value (US$ Million) Analysis by Type, 2018 to 2033

Figure 69: Europe Market Value Share (%) and BPS Analysis by Type, 2023 to 2033

Figure 70: Europe Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033

Figure 71: Europe Market Value (US$ Million) Analysis by  Molecule Types, 2018 to 2033

Figure 72: Europe Market Value Share (%) and BPS Analysis by  Molecule Types, 2023 to 2033

Figure 73: Europe Market Y-o-Y Growth (%) Projections by  Molecule Types, 2023 to 2033

Figure 74: Europe Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 75: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 76: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 77: Europe Market Attractiveness by Type, 2023 to 2033

Figure 78: Europe Market Attractiveness by  Molecule Types, 2023 to 2033

Figure 79: Europe Market Attractiveness by Route of Administration, 2023 to 2033

Figure 80: Europe Market Attractiveness by Country, 2023 to 2033

Figure 81: South Asia Market Value (US$ Million) by Type, 2023 to 2033

Figure 82: South Asia Market Value (US$ Million) by  Molecule Types, 2023 to 2033

Figure 83: South Asia Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 88: South Asia Market Value (US$ Million) Analysis by Type, 2018 to 2033

Figure 89: South Asia Market Value Share (%) and BPS Analysis by Type, 2023 to 2033

Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033

Figure 91: South Asia Market Value (US$ Million) Analysis by  Molecule Types, 2018 to 2033

Figure 92: South Asia Market Value Share (%) and BPS Analysis by  Molecule Types, 2023 to 2033

Figure 93: South Asia Market Y-o-Y Growth (%) Projections by  Molecule Types, 2023 to 2033

Figure 94: South Asia Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 95: South Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 96: South Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 97: South Asia Market Attractiveness by Type, 2023 to 2033

Figure 98: South Asia Market Attractiveness by  Molecule Types, 2023 to 2033

Figure 99: South Asia Market Attractiveness by Route of Administration, 2023 to 2033

Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033

Figure 101: East Asia Market Value (US$ Million) by Type, 2023 to 2033

Figure 102: East Asia Market Value (US$ Million) by  Molecule Types, 2023 to 2033

Figure 103: East Asia Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 108: East Asia Market Value (US$ Million) Analysis by Type, 2018 to 2033

Figure 109: East Asia Market Value Share (%) and BPS Analysis by Type, 2023 to 2033

Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033

Figure 111: East Asia Market Value (US$ Million) Analysis by  Molecule Types, 2018 to 2033

Figure 112: East Asia Market Value Share (%) and BPS Analysis by  Molecule Types, 2023 to 2033

Figure 113: East Asia Market Y-o-Y Growth (%) Projections by  Molecule Types, 2023 to 2033

Figure 114: East Asia Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 115: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 116: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 117: East Asia Market Attractiveness by Type, 2023 to 2033

Figure 118: East Asia Market Attractiveness by  Molecule Types, 2023 to 2033

Figure 119: East Asia Market Attractiveness by Route of Administration, 2023 to 2033

Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 121: Oceania Market Value (US$ Million) by Type, 2023 to 2033

Figure 122: Oceania Market Value (US$ Million) by  Molecule Types, 2023 to 2033

Figure 123: Oceania Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033

Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 128: Oceania Market Value (US$ Million) Analysis by Type, 2018 to 2033

Figure 129: Oceania Market Value Share (%) and BPS Analysis by Type, 2023 to 2033

Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033

Figure 131: Oceania Market Value (US$ Million) Analysis by  Molecule Types, 2018 to 2033

Figure 132: Oceania Market Value Share (%) and BPS Analysis by  Molecule Types, 2023 to 2033

Figure 133: Oceania Market Y-o-Y Growth (%) Projections by  Molecule Types, 2023 to 2033

Figure 134: Oceania Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 135: Oceania Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 136: Oceania Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 137: Oceania Market Attractiveness by Type, 2023 to 2033

Figure 138: Oceania Market Attractiveness by  Molecule Types, 2023 to 2033

Figure 139: Oceania Market Attractiveness by Route of Administration, 2023 to 2033

Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033

Figure 141: MEA Market Value (US$ Million) by Type, 2023 to 2033

Figure 142: MEA Market Value (US$ Million) by  Molecule Types, 2023 to 2033

Figure 143: MEA Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033

Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 148: MEA Market Value (US$ Million) Analysis by Type, 2018 to 2033

Figure 149: MEA Market Value Share (%) and BPS Analysis by Type, 2023 to 2033

Figure 150: MEA Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033

Figure 151: MEA Market Value (US$ Million) Analysis by  Molecule Types, 2018 to 2033

Figure 152: MEA Market Value Share (%) and BPS Analysis by  Molecule Types, 2023 to 2033

Figure 153: MEA Market Y-o-Y Growth (%) Projections by  Molecule Types, 2023 to 2033

Figure 154: MEA Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 155: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 156: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 157: MEA Market Attractiveness by Type, 2023 to 2033

Figure 158: MEA Market Attractiveness by  Molecule Types, 2023 to 2033

Figure 159: MEA Market Attractiveness by Route of Administration, 2023 to 2033

Figure 160: MEA Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Kinase Inhibitors For Cancer Treatment Market

Published : November 2022

Healthcare

PARP Inhibitors Market

Published : July 2022

Explore Healthcare Insights

View Reports

Isocitrate Dehydrogenase (IDH) Inhibitors Market